Pfizer Inc said on Wednesday it had offered to provide Brazil with millions of doses of a COVID-19 vaccine in the first half of 2021, amid evidence the coronavirus is spreading more rapidly in South America’s largest country.
“Pfizer made a proposal to the Brazilian government, in line with deals we closed in other countries - including in Latin America, that would permit the vaccination of millions of Brazilians in the first half, subject to regulatory approval,” the company said in a statement.
Read the latest updates in our dedicated coronavirus section.
Brazil has the third-worst outbreak of coronavirus in the world by number of cases, after the US and India.
On Tuesday, the Imperial College London released data showing that the rate of infection in Brazil had accelerated to 1.1, meaning every 100 people with coronavirus infect 110 people. That is the first time in weeks the figure has been above one.
Brazil’s Health Ministry said it met with Pfizer on Tuesday and would buy the vaccine if proven safe and if health regulator Anvisa registered it. The ministry said it will also meet this week with Johnson & Johnson
Anvisa has signed off on rules to accelerate COVID-19 vaccine approvals, according to a notice published in the government gazette on Wednesday.
The new rules allow labs to present data to Anvisa continuously as it is generated rather than waiting for all documentation to be complete. Regulatory impact analyzes and public consultations that are normally required will also be waived.
Coronavirus: Pfizer, Moderna COVID-19 vaccines ready for US authorization in weeksPfizer Inc’s and Moderna Inc’s COVID-19 vaccine candidates could be ready for US authorization and distribution within weeks, setting the stage for ... Coronavirus
Coronavirus: Pfizer says COVID-19 vaccine 95 percent effectivePfizer Inc said on Wednesday that final results from the late-stage trial of its COVID-19 vaccine show it was 95 percent effective, adding it had the ... Coronavirus
Coronavirus: How Pfizer, Moderna sprinted ahead in race for COVID-19 vaccineJust as the novel coronavirus was gaining a foothold in the United States in mid-March, Pfizer Inc Chief Executive Albert Bourla called on his top ... Coronavirus